The Endocrine Board Review (EBR) 2026 Study Session Recordings include nine hours of content from the live sessions held September 18–20, 2026. Before the program, participants completed the Interactive Practice Exams, giving faculty insight into the topics that required additional review. Faculty who contributed to Endocrine Board Review Book - 18th Edition (2026) then used performance data, participant feedback, and submitted questions to shape the live discussions.
In these recordings, faculty address:
The recordings complement Endocrine Board Review Book - 18th Edition (2026), and the Interactive Practice Exams by providing deeper discussion of complex topics across the major content areas in the ABIM Endocrinology, Diabetes, and Metabolism Certification Examination blueprint.
The nine hours of recordings cover the major content areas represented in the ABIM Endocrinology, Diabetes, and Metabolism Certification Examination blueprint.
Strengthen your preparation for certification or recertification with focused explanations of the questions, cases, and endocrine concepts that challenged participants during the live Endocrine Board Review 2026 study sessions.
Earn up to 9 AMA PRA Category 1 Credits™.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates the Endocrine Board Review 2026 Study Session Recordings for a maximum of 9 AMA PRA Category 1 Credits™.
Successful completion of this CME activity includes participation in the activity evaluation. After completing the activity evaluation, participants will be able to save or print a CME certificate.
CME credits for the Endocrine Board Review 2026 Study Sessions Recordings activity related to this material must be claimed by December 31, 2027.
AMA PRA Category 1 CreditThe Endocrine Society designates the Endocrine Board Review 2026 Live Study Sessions for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
For questions about content or obtaining CME credit, please contact the Endocrine Society at [email protected].
As a provider of CME accredited by the ACCME, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's EBR faculty. There are no commercial supporters of this activity, and no commercial entities have had influence over the planning of this CME activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships:
Irina Bancos, MD, Adrenas, Corcept, Esteve, Recordati, Xeris (Advisory Board); Adaptyx, Astrazeneca, Camurus, Corcept, Crinetics, Diurnal, Esteve, Neurocrine, Recordati, Sparrow Pharmaceutics, Spruce (Consultant); European Journal of Endocrinology (Editor); Esteve, Recordati (Research Support); Dynamed (Reviewer); Elsevier (Writer).
Shagun Bindlish, MD, Golden State Obesity Society (Founder and President), American Diabetes Association journal Clinical Diabetes, Obesity Medicine Association journal Pillars of Medicine (Associate Editor).
John D. Carmichael, MD, American Association of Clinical Endocrinologists and Pituitary Society (Member); Novo Nordisk, Camurus, Xeris (Advisory Board); Crinetics, Novo Nordisk (Research Support).
Marcelo Correia, MD, MSc, PhD, The Obesity Society (Member); Novartis, Eli Lilly, Novo Nordisk, Stead Family (Iowa), National Institutes of Health, PCORI (Research Support); Novo Nordisk (Advisory Board and Consultant); Genentech/Roche (Advisory Board).
Natalie Cusano, MD, MS, Ascendis Pharma, Extend Biosciences (Consultant); Endocrine Practice (Editor); Ascendis Pharma, Takeda/Shire (Research Support); Alexion (Speaker).
Kaniksha Desai, MD, Endocrine Practice (Editor); American Thyroid Association, American Association of Clinical Endocrinologists, Thyroid Disease State Network (Member); Medscape Podcast on Thyroid Diseases (Host).
Hans K. Ghayee, DO, Corcept (Consultant); SDHB Pheo Para Coalition (Funding); University of Texas Southwestern Medical Center (Royalties).
Sangeeta Kashyap, MD, GI Dynamics (Consultant); Fractyl, Inc (Research Support).
E. Michael Lewiecki, MD, Ultragenyx, Angitia (Institutional Research Grants); Amgen, Radius, Kyowa Kirin, Angitia, Ascendis (Consultant); Amgen, Radius, Ascendis, Kyowa Kirin (Speaker).
Cecilia C. Low Wang, MD, American Association of Clinical Endocrinology, American College of Diabetology, American Heart Association, Clinical Diabetes and Endocrinology Institute (Advisory Board); Clinical Diabetes and Endocrinology Institute, Medical Education Resources, Continuing Education Company (Speaker); Dexcom Inc, Virta Health (Research Funding); American Heart Association (Guidelines Committee); FDA Advisory Committee for Endocrinologic Metabolic Drugs (Committee Member).
Elizabeth McAninch, MD, Acella Pharmaceuticals, AbbVie Inc (Consultant); Equilibrate Therapeutics, LLC (Cofounder).
Stephanie Page, MD, PhD, Pharmajor International (Consultant).
The following faculty reported no relevant financial relationships: Dima L. Diab, MD; Margaret Flynn Lippincott, MD; Aniket Sidhaye, MD; and Catherine D. Zhang, MD.
The medical editor for this activity reported no relevant financial relationships: Abbie L. Young, MS, CGC, ELS(D)
Endocrine Society staff involved in developing content for this activity reported no relevant financial relationships.
Content Licensing
Contact us to learn more about licensing solutions for your organization.
